Bryan Kobel

CEO at TC BioPharm $TCBP

[TC BioPharm @TCBioPharm]

$TCBP Announces Grant of European #Patent for Targeting of Microbial, #Oncological, and Viral Indications using Modified Gamma Delta T Cells

https://t.co/jXHHjENZzd

[Bryan Kobel @CEO_TCBioPharm]

@123Kiki @Unluckiest2083 the stock closed below $1 for 30 days as part a short and distort campaign that was placed against the company last fall. This delisting is a result of that.

[Bryan Kobel @CEO_TCBioPharm]

@Unluckiest2083 This attack on company stock price was a direct result of fraud. Subsequently, we put in front of Nasdaq panel a very strong case showing our commitment and track record of compliance. They moved to delist us.

[Bryan Kobel @CEO_TCBioPharm]

@Unluckiest2083 $TCBP was part of a "short and distort" campaign. We made a concerted effort but the stock never recovered and "closed", not "traded" below $1 for 30 straight days. We chose not to split the stock because we had several key announcements and hoped to avoid hurting investors.

[Bryan Kobel @CEO_TCBioPharm]

@seoljaeryong @TCBioPharm If you have a legitimate question, I encourage you to reach out to our company directly. [email protected]

[TC BioPharm @TCBioPharm]

$TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

The company is expected to reduce core operational burn by 55% when compared to 2024

https://t.co/Nhg7ODF5e2

[Bryan Kobel @CEO_TCBioPharm]

@seoljaeryong @TCBioPharm Management's goal is to enhance shareholder value

[Bryan Kobel @CEO_TCBioPharm]

@benchling @BBCNews @sajithw Great to hear this type of #optimism in the #biotech space

[Bryan Kobel @CEO_TCBioPharm]

@seoljaeryong @TCBioPharm Financing terms will be disclosed when appropriate

[TC BioPharm @TCBioPharm]

$TCBP Announces Non-Binding Letter of Intent to #Acquire #Commercial #Stage Ophthalmic Pharmaceutical Company

https://t.co/LujJ7sDmYX

[Bryan Kobel @CEO_TCBioPharm]

@TCBioPharm Looking forward to seeing everyone here:

https://t.co/F5IUCZ1Qgy

[TC BioPharm @TCBioPharm]

$TCBP @CEO_TCBioPharm to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

https://t.co/FDisyx9MD1

[Bryan Kobel @CEO_TCBioPharm]

@Jzekester35 I certainly am not halting any "market runs".

[Bryan Kobel @CEO_TCBioPharm]

@professorDman1 We're actively communicating updates to the market, speaking with investors and working diligently to progress clinical trials.

[TC BioPharm @TCBioPharm]

https://t.co/B7K0K8A68o

[Bryan Kobel @CEO_TCBioPharm]

@hyjr2 @TCBioPharm The conference was well attended and we held individual meetings with perspective investors on-site. We are also speaking with relevant investors regularly.

[Bryan Kobel @CEO_TCBioPharm]

@Jzekester35 @TCBioPharm While we can't comment on stock activity, we can continue to work on the development of much-needed, novel treatments.

[TC BioPharm @TCBioPharm]

$TCBP Announces #H5N1 Proof of Concept Studies Intention

https://t.co/3OmuKHC2Qn

[Bryan Kobel @CEO_TCBioPharm]

@2DMoon828741 We are and will continue to communicate any and all news to shareholders as it becomes available.

[Bryan Kobel @CEO_TCBioPharm]

$TCBP shareholders,

As stated in our 6k, the Company intends to appeal the notice to the Nasdaq Panel. This follows the same process we previously followed when receiving these notices from Nasdaq when we were in deficiency status.